Literature DB >> 21509766

B-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia.

Mascha Binder1, Fabian Müller, Antje Jackst, Barbara Léchenne, Milena Pantic, Ulrike Bacher, Christine Zu Eulenburg, Hendrik Veelken, Roland Mertelsmann, Renata Pasqualini, Wadih Arap, Martin Trepel.   

Abstract

BACKGROUND: B-cell receptors (BCRs) and their recognition of specific epitopes may play a pivotal role in the development and progression of chronic lymphocytic leukemia (CLL). In this study, the authors set up a model system to explore epitope reactivity and its clinical relevance in CLL.
METHODS: Epitope-mimicking peptides were selected from phage display libraries on 6 CLL BCRs from randomly chosen patients. The binding of the 6 index epitope mimics was evaluated in a set of 100 unrelated CLL samples. Epitope recognition patterns were correlated with the clinical course of the disease.
RESULTS: Surprisingly, all CLL samples recognized 1 or several index epitopes, and some revealed marked polyreactivity. Patients with CLL who expressed BCRs that reacted with ≥5 epitope mimics had a significantly worse clinical course than less polyreactive patients (median time to first treatment, 24 months vs 102 months). This effect was independent of otherwise known prognostic markers.
CONCLUSIONS: The authors introduced a system with which to model epitope reactivity of CLL BCRs without previous knowledge of potential antigens. The findings indicated that a polyreactive epitope recognition pattern may be a determinant of an aggressive clinical course in this disease. This further emphasizes the functional and prognostic relevance of BCR epitope recognition in CLL.
Copyright © 2010 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21509766     DOI: 10.1002/cncr.25755

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8.

Authors:  Maria Gounari; Stavroula Ntoufa; Benedetta Apollonio; Nikos Papakonstantinou; Maurilio Ponzoni; Charles C Chu; Davide Rossi; Gianluca Gaidano; Nicholas Chiorazzi; Kostas Stamatopoulos; Paolo Ghia
Journal:  Blood       Date:  2015-04-21       Impact factor: 22.113

2.  Complementarity determining region-independent recognition of a superantigen by B-cell antigen receptors of mantle cell lymphoma.

Authors:  Michael Fichtner; Elmar Spies; Henning Seismann; Kristoffer Riecken; Niklas Engels; Barbara Gösch; Judith Dierlamm; Helwe Gerull; Peter Nollau; Wolfram Klapper; Martin Dreyling; Mascha Binder; Martin Trepel
Journal:  Haematologica       Date:  2016-09       Impact factor: 9.941

3.  Chronic lymphocytic leukemia: a tale of one or two signals?

Authors:  Nicholas Chiorazzi; Dimitar G Efremov
Journal:  Cell Res       Date:  2012-11-13       Impact factor: 25.617

Review 4.  Targeting the B-cell receptor signaling pathway in B lymphoid malignancies.

Authors:  Maike Buchner; Markus Müschen
Journal:  Curr Opin Hematol       Date:  2014-07       Impact factor: 3.284

5.  Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab.

Authors:  Mareike Voigt; Friederike Braig; Markus Göthel; Alexander Schulte; Katrin Lamszus; Carsten Bokemeyer; Mascha Binder
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

6.  Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling.

Authors:  Marcus Dühren-von Minden; Rudolf Übelhart; Dunja Schneider; Thomas Wossning; Martina P Bach; Maike Buchner; Daniel Hofmann; Elena Surova; Marie Follo; Fabian Köhler; Hedda Wardemann; Katja Zirlik; Hendrik Veelken; Hassan Jumaa
Journal:  Nature       Date:  2012-09-13       Impact factor: 49.962

Review 7.  B-cell receptor signaling as a driver of lymphoma development and evolution.

Authors:  Carsten U Niemann; Adrian Wiestner
Journal:  Semin Cancer Biol       Date:  2013-09-20       Impact factor: 15.707

Review 8.  SLAMF6 in health and disease: Implications for therapeutic targeting.

Authors:  Burcu Yigit; Ninghai Wang; Roland W Herzog; Cox Terhorst
Journal:  Clin Immunol       Date:  2018-10-23       Impact factor: 3.969

Review 9.  Immunological aspects in chronic lymphocytic leukemia (CLL) development.

Authors:  Ricardo García-Muñoz; Verónica Roldan Galiacho; Luis Llorente
Journal:  Ann Hematol       Date:  2012-04-12       Impact factor: 3.673

10.  Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.

Authors:  Kathleen J Till; Andrew R Pettitt; Joseph R Slupsky
Journal:  J Immunol       Date:  2015-01-28       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.